Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viva Biotech HoldingsFRA:VB0 -2.86%43 EV-to-OCF is 13.80 as of Aug. 13, 2026, which is 72% below its 10-year median of 49.88. GuruFocus rates FRA:VB0 with a GF Score™ of 43/100 and a GF Value™ of €0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,408 Biotechnology companies, Viva Biotech Holdings ranks worse than 85.37% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Viva Biotech Holdings's Enterprise Value is €387.7 Mil.
Viva Biotech Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €28.1 Mil. Therefore, Viva Biotech Holdings's EV-to-OCF for today is 13.80.
The historical rank and industry rank for Viva Biotech Holdings's EV-to-OCF or its related term are showing as below:
FRA:VB0'
s EV-to-OCF Range Over the Past 10 Years
Min: 4.27 Med: 49.88 Max: 543.47
Current: 13.77
During the past 10 years, the highest EV-to-OCF of Viva Biotech Holdings was 543.47. The lowest was 4.27. And the median was 49.88.
FRA:VB0's EV-to-OCF is ranked worse than 85.37% of 1408
companies
in the Biotechnology industry
Industry Median: -3.53
vs FRA:VB0: 13.77
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Viva Biotech Holdings's PE Ratio (TTM) for today is calculated as:
Viva Biotech Holdings's share price for today is €0.17.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Viva Biotech Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.011.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Viva Biotech Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's EV-to-OCF falls into.
Viva Biotech Holdings's current Enterprise Value is €387.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Viva Biotech Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €28.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viva Biotech Holdings (FRA:VB0) has a EV-to-OCF of 13.80 as of Aug. 13, 2026. This is 72% below median its historical median of 49.88. Over the past decade, Viva Biotech Holdings' EV-to-OCF has ranged from 4.27 to 543.47. According to the industry distribution chart, Viva Biotech Holdings ranks #1202 out of 1408 companies in the Biotechnology industry, placing it in the top 85.4%.
Is Viva Biotech Holdings' EV-to-OCF too high?
Viva Biotech Holdings' current EV-to-OCF of 13.80 is 72% below median its 10-year median of 49.88. Over the past 10 years, this metric has ranged from a low of 4.27 to a high of 543.47. Based on the distribution chart, Viva Biotech Holdings ranks #1202 out of 1408 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Viva Biotech Holdings has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viva Biotech Holdings' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Viva Biotech Holdings ranks #1202 out of 1408 companies for EV-to-OCF. This places Viva Biotech Holdings in the lower half of its industry. Historically, Viva Biotech Holdings' own EV-to-OCF has ranged from 4.27 to 543.47 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Viva Biotech Holdings's current EV-to-OCF is 13.80, which is 72% below median its own 10-year median of 49.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viva Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Viva Biotech Holdings (FRA:VB0) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.08, compared to a current price of €0.17 — trading 112.5% above its estimated fair value. The current EV-to-OCF is 13.80, which is 72% below median its 10-year median of 49.88. Viva Biotech Holdings' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Viva Biotech Holdings (FRA:VB0), the current EV-to-OCF is 13.80 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viva Biotech Holdings (FRA:VB0) Overvalued in 2026?
Based on GuruFocus' analysis, Viva Biotech Holdings stock appears to be overvalued.
The current stock price of €0.17 is trading 112.5% above its estimated GF Value™ of €0.08.
GuruFocus considers Viva Biotech Holdings to be Significantly Overvalued.
Key valuation signals for FRA:VB0:
EV-to-OCF: 13.80 (72% below median its 10-year median of 49.88)
GF Value™: €0.08 vs. price of €0.17 (112.5% above fair value)
No single metric tells the full story. See the FRA:VB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies.
43GF Score
Get the complete analysis for FRA:VB0
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VB0 has been successfully added to your 
